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Abbreviations: BR, bilirubin; DMPC, 1,2-Dimyristoyl-sn-glycero-3-phosphorylcholine; EPR, electron 
paramagnetic resonance; MDA, malondialdehyde; PA, penicillamine.  
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Abstract 
 
Toxic effects of unconjugated bilirubin (BR) in neonatal hyperbilirubinemia have been related to 
redox and/or coordinate interactions with Cu
2+
. However, the development and mechanisms of such 
interactions at physiological pH have not been resolved. This study shows that BR reduces Cu
2+
 to 
Cu
1+
 in 1:1 stoichiometry. Apparently, BR undergoes degradation, i.e. BR and Cu
2+
 do not form stable 
complexes. The binding of Cu
2+
 to inorganic phosphates, liposomal phosphate groups, or to chelating 
drug penicillamine, impedes redox interactions with BR. Cu
1+ 
undergoes spontaneous oxidation by O2 
resulting in hydrogen peroxide accumulation and hydroxyl radical production. In relation to this, 
copper and BR induced synergistic oxidative/damaging effects on erythrocytes membrane, which 
were alleviated by penicillamine. The production of reactive oxygen species by BR and copper 
represents a plausible cause of BR toxic effects and cell damage in hyperbilirubinemia. Further 
examination of therapeutic potentials of copper chelators in the treatment of severe neonatal 
hyperbilirubinemia is needed. 
 
 
Keywords: Erythrocytes; Hydrogen peroxide; Hyperbilirubinemia; Lipid peroxidation; Superoxide 
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1. Introduction 
 
Hyperbilirubinemia, the accumulation of bilirubin (BR) in the plasma and tissues, is often observed in 
newborns. It develops due to high turnover of erythrocytes and hepatic immaturity, but also in 
relation to some pathological conditions, such as hemolytic diseases and sepsis [1,2]. BR levels 
exceeding physiological concentrations more than 20-fold, labeled as severe hyperbilirubinemia, may 
result in neural damage, promoted hemolysis and general cellular injury, and increased risk of sepsis 
[3–5]. The treatment of severe hyperbilirubinemia relies on exchange transfusions, which show 
considerable rate of complications (~10%), including infections, venous thrombosis, 
thrombocytopenia, and necrotizing enterocolitis [3,6]. In order to develop safer therapeutic 
approaches, it is essential to understand the molecular mechanisms of BR toxicity.  
It has been recognized that pathologic phenotypes of hyperbilirubinemia are primarily due to 
unconjugated BR (not bound to albumin) [7]. BR is produced in the second step of heme (porphyrin) 
catabolic pathway via two-electron reduction of biliverdin [8]. As such, BR represents an electron-rich 
molecule with potential to form multiple coordinate bonds (e.g. via N in four pyrrole moieties), with 
specific redox-active metals [9]. Pertinent to this, it has been contemplated that detrimental effects 
of hyperbilirubinemia may come from redox/coordinate interactions of BR with copper [10]. There is 
a substantial amount of indirect evidence for this: (i) several clinical studies have found beneficial 
effects of copper-chelation therapy with penicillamine (PA) in neonatal hyperbilirubinemia [11–13]; 
(ii) neonates with hyperbilirubinemia show increased plasma levels of copper [14]; (iii) neural injury 
in hyperbilirubinemia occurs primarily in basal ganglia [3], which show higher copper content 
compared to other brain regions [15]; and (iv) a number of studies have found signs of oxidative 
stress, including lipid peroxidation and depletion of major antioxidants - ascorbate and thiols, in the 
plasma of neonates with hyperbilirubinemia [16–18]. On the other hand, reports on BR-Cu
2+
 
biochemistry at physiological pH are inconsistent, proposing the formation of stable coordination
 
complexes with different stoichiometries [19–21], as well as Cu
2+
 reduction by BR with accompanying 
generation of reactive oxygen species [22,23]. It is worth mentioning that some studies of BR-Cu
2+
 
system have been performed at pH > 8 [24,25]. Those appear to be of little relevance for explaining 
processes in the plasma (pH = 7.4), taking into account that pK values for BR are above 8 [26].  
We set out to examine in detail the interactions of BR and Cu
2+
 at plasma pH, and to evaluate the 
effects of PA on this system, using spectrophotometry, electrochemical methods, and electron 
paramagnetic resonance (EPR) spectroscopy. In addition, biochemical assays were applied to 
examine the effects of BR and copper on the membrane of human erythrocytes. 
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2. Material and Methods 
 
2.1. Chemicals 
All chemicals were of analytical grade: BR (>98% purity), CuCl2, D-penicillamine, catalase (CAT; 
C1345), 1,2-dimyristoyl-sn-glycero-3-phosphocholine (DMPC), buffer components (Sigma-Aldrich, St. 
Louis, MO,  USA), CuCl (Merck, Kenilworth, NJ, USA), FeCl3 (Analytika Ltd., Prague, Czech Republic). 
All experiments were performed using bidistilled deionized ultrapure (18 MΩ) water. Stock solutions 
of BR (1 mM) in 5 mM NaOH, PA, and CuCl (prepared in 1 M HCl; an aliquot of 1 M NaOH was used to 
neutralize the acid), as well as phosphate buffer (50 mM KH2PO4; pH 7.4), and phosphate buffer 
saline (PBS: 10  mM Na2HPO4, 2 mM KH2PO4, 137 mM NaCl, 2.7 mM KCl; pH 7.4) were prepared each 
day, and kept light-protected on ice if needed. Incubation and measurements were conducted in the 
dark at 293 K, except for experiments with erythrocytes (310 K). 
2.2. UV/VIS spectroscopy 
UV-Vis absorption spectra were obtained using 2501 PC Shimadzu spectrophotometer (Kyoto, Japan), 
using the following settings:  sample volume, 1 mL; scan range 800–250 nm; scan time, 50 s; initial 
scan, 30 s after sample preparation; follow up period, 30 min. 
2.3. Cyclic and differential pulse voltammetry 
The voltammetric measurements were performed using a potentiostat/galvanostat CHI 760b (CH 
Instruments Inc., Austin, TX, USA), controlled by corresponding electrochemical software. The 
electrochemical cell was equipped with a boron-doped diamond electrode embedded in a polyether 
ether ketone body with an inner diameter of 3 mm, resistivity of 0.075 Ω cm, and boron doping level 
of 1000 ppm (Windsor Scientific Ltd., Slough, UK). This was the working electrode, with Ag/AgCl (3 M 
KCl) reference electrode (potentials reported in this paper are referred versus this electrode), and a 
Pt wire as a counter electrode. Scan rate was 0.1 V/s. Differential pulse voltammetry was performed 
on the same instrument using the following settings: initial E, 0.5 V; final E, -0.5 V; increment, 0.004 
V; amplitude, 0.05 V; pulse width, 0.05 s; sample width, 0.01 s; quiet time, 2 s. Cyclic voltammetry 
measurements were performed in water, pH 5. The pH of each system was measured after mixing all 
components, and carefully adjusted to ~5 with HCl (100 mM). The established aliquots of HCl were 
added to BR solution or water prior to the formation of each system. Measurements were initiated 
immediately after sample preparation. 
2.4. EPR spectroscopy 
Measurements at 110 K were conducted on a Bruker Elexsys-II EPR spectrometer operating at X-band 
(9.4 GHz), with Bruker N2 Temperature Controller ER4131VT, and the following settings: microwave 
power, 3.17 mW; scan time, 80 s; modulation amplitude, 0.5 mT; modulation frequency, 100 kHz; 
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number of accumulations, 4. All spectra were baseline corrected. DMPC liposomes (62.5 mg/mL final 
concentration of lipids) were prepared in water according to the previously described protocol [27]. 
Samples were placed in quartz EPR tubes and quickly frozen in cold isopentane after 30 s of 
incubation.  
2.5. Oximetry 
The concentration of O2 was determined using a Clark type oxygen electrode (Hansatech Instruments 
Ltd., King's Lynn, UK) operating with Lab Pro interface and Logger Pro 3 software (Vernier, Beaverton, 
OR, USA). All systems were recorded for 2–5 min before the addition of BR to establish the stability 
of baseline and zero rate of O2 change. Decrease in [O2] was monitored for 10 min and then CAT (200 
IU) was added to determine the concentration of H2O2, which corresponds to the double 
concentration of CAT-induced O2 release (mechanism of CAT activity: 2H2O2 → 2H2O + O2) [28].   
2.6. Effects on erythrocytes 
Erythrocytes were obtained from five healthy volunteers using Vacutainer tubes containing K3EDTA 
as the anticoagulant (BD, Franklin Lakes, NJ, USA), and centrifugation (2000 g/10 min/4
o
C). Buffy coat 
was carefully removed, and erythrocytes were washed 3× and re-suspended in PBS. Following 5 min 
of incubation at 310 K with gentle shaking, supernatants were collected by centrifuged. 
Malondialdehyde (MDA) levels were measured using previously described method [29]. In brief, 
MDA reacts with thiobarbituric acid in acidic conditions at 100
o
C to form pink colored complex. MDA 
concentration was calculated using the absorbance at 535 nm and molar extinction coefficient  of 
1.56 × 10
5
 L mol
-1 
cm
-1
. Extracellular Hb was measured as cyanmethemoglobin using the Drabkin 
method [30]. 
2.7. Statistical analysis 
All experiments were performed at least in triplicate (experiments on erythrocytes were repeated 
five times). Data are presented as mean ± S.D. Statistical significance was established via 
nonparametric two-tailed Mann–Whitney U test (for two sample groups) or one-way ANOVA with 
post hoc Duncan's range test (for >2 sample groups). The limit of statistical significance was p < 0.05. 
  
3. Results and Discussion 
 
UV-Vis spectrophotometry was applied to investigate potential development of BR:Cu
2+
 complexes 
(the formation of coordinate bonds results into the d-orbital splitting that may lead to absorption in 
the visible range), or BR degradation. It can be observed that the characteristic band of BR (λmax = 435 
nm) was diminished within 10 min in the presence of copper, and that the maximum was shifted to 
400 nm (Fig. 1a). In parallel with this, a weak line at 330 nm and a broad 'tail' in the upper field, 
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emerged. The intensity of λmax = 400 nm peak and the 'tail' further decreased with time, whereas an 
additional line at λmax ~655 nm slowly developed. The later may come from a small amount of 
biliverdin (about 20 μM; calculated from UV-Vis spectra of biliverdin (not shown)), which has λmax at 
670 nm [31]. Changes in the UV-Vis spectra imply that BR and Cu
2+
 do not form stable complex(es). 
The results speak in favor of Cu
2+
-induced degradation of BR with multiple derivatives and secondary 
products. This is in accordance with previous reports on the irreversible degradation of BR that was 
exposed to oxidizing agents [31]. In the absence of copper, BR was stable in the phosphate buffer 
(Fig. 1b). Only a small decrease in the intensity of 435 nm band was observed, which may be 
attributed to precipitation, since BR is not deprotonated/charged at pH = 7.4 [26]. Similar results 
were obtained in the presence of Fe
3+
, implying that BR and Fe
3+
 do not develop coordinate or redox 
interactions. This can be put into the context of Pearson HSAB principle. Pyrrole is a borderline Lewis 
base, whereas Cu
2+
 and Fe
3+
 are a borderline acid and a hard acid, respectively [32]. Accordingly, the 
affinity of BR is higher for Cu
2+
 than for Fe
3+
. Cu
2+
 and BR probably form a transient complex, which is 
followed by electron transfer. 
Cyclic voltammetry was applied to examine redox behavior of copper in the presence of BR. The 
experiments were conducted in water (pH ~5), because copper-related currents were attenuated in 
the phosphate buffer. Pertinent to this, speciation diagrams implicate complete solubility of Cu
2+
 in 
water at pH 5, which was not the case for phosphate buffer at pH 7.4 (Supplementary Fig. 1). Cu
2+
 
and Cu
1+
 showed peak currents (ip) at different oxidation/anodic (Epa) and reduction/cathodic (Epc) 
potentials (Fig. 2a). The assignation was in accordance with the standard potentials of Cu
2+
 and Cu
1+
 
[33]. All these peaks were present in cyclic voltammograms of the system with Cu
2+
 and BR, but with 
weaker ip (Fig. 2b), probably because of the adhesion/interference of BR on/with the electrode 
surface. Still, changes of ip of Cu
2+
 (at Epa = 265 mV and Epc = -217 mV) and Cu
1+
 (at Epa = 135 mV and 
Epa = 534 mV) were evident. Currents assigned to Cu
1+
 showed a time-dependent drop that was 
accompanied by the rise of Cu
2+
 currents. Apparently, BR induced a reduction of Cu
2+
 to Cu
1+
, which 
was followed by spontaneous oxidation of Cu
1+
. To determine the stoichiometry of BR-induced 
reduction of Cu
2+
, a differential pulse voltammetry of ipc of Cu
2+ 
→ Cu
1+
 was applied (Fig. 2c). Using a 
calibration curve, it was determined that the concentration of remaining Cu
2+
 in the system with 
initial Cu
2+
 and BR concentrations of 0.4 and 0.2 mM, respectively, was 0.25 ± 0.04 mM. In other 
words, the amount of Cu
2+
 that was reduced was similar to BR concentration, implying that BR 
reduces Cu
2+
 in 1:1 stoichiometry. This is in accordance with some previous estimates [21].  
Low-T EPR is a method of choice for examining Cu
2+
 complexes [34]. It also delivers info on Cu
2+
 
reduction, since Cu
1+
 is an EPR 'silent' species (S = 0). Voltammetry showed that BR-induced 
reduction of Cu
2+
 was fast (Fig. 2), so the EPR spectra were collected after 30 s incubation period. Fig. 
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3a shows characteristic EPR spectrum of Cu
2+
 in axial symmetry with one strong g┴ line and four weak 
lines coming from hyperfine coupling with 
63
Cu/
65
Cu nuclei (I = 3/2) along g║ [35]. The signal was 
drastically decreased in the presence of BR. This is in line with the proposed BR-induced reduction of 
Cu
2+
 to Cu
1+
, and with the absence of stable BR:Cu
2+
 complex(es) at physiological pH. Although the 
concentration ratio between BR and Cu
2+
 was 1:1, not all Cu
2+
 was reduced, which appears not to be 
in accord with the results obtained by differential pulse voltammetry (Fig. 2c). However, the 
discrepancy could be easily explained by different speciation of Cu
2+
 in phosphate buffer at pH 7.4 
(EPR experiments), compared to copper in water at pH 5 (voltammetry). Namely, a fraction of Cu
2+
 at 
pH 7.4 is present in the form of a non-soluble phosphates (Supplementary Fig. 1), which may not be 
accessible for BR-induced reduction. The remaining Cu
2+
 signal in the presence of BR showed a 
broader g┴ line compared to the initial Cu
2+
 spectrum, whereas lines from hyperfine coupling could 
not be observed. This may be a result of inhomogenous broadening due to anisotropic interactions 
or an unresolved hyperfine structure of Cu
2+
 in the solid state [36].  
Next, we examined whether chelating agent PA can prevent BR-induced reduction. The spectrum of 
Cu
2+
 in the presence of PA appears to include two components: a broad signal of Cu
2+
 chelated by PA, 
and the signal of Cu
2+
 in the phosphate buffer (Fig. 3b). The broadening of the signal of PA-bound 
Cu
2+
 has been attributed to the dipolar interactions between multiple paramagnetic Cu
2+
 ions within 
PA-copper clusters [37]. The incubation with BR diminished the signal of 'free' Cu
2+
, whereas the 
signal of Cu
2+
-PA complex was only slightly affected. This implies that Cu
2+
 within the cluster is 
inaccessible to BR. In addition, we were interested whether BR can reduce Cu
2+
 that is bound to 
phospholipids [38]. DMPC liposomes were used as a model membrane. The spectrum of Cu
2+
 in the 
presence of liposomes showed g-values that were similar to the position of lines for Cu
2+
 in the 
phosphate buffer (Fig. 3c). This implies that Cu
2+
 binds to phospholipids via phosphate groups, which 
show very low pKa values and hence bear negative charges [39]. BR did not significantly affect the 
intensity of signal of liposome-bound Cu
2+
, but it caused some broadening of g┴ line. This implicates 
that Cu
2+
 bound to membranes is poorly accessible to BR. The broadening might be related to 
formation of BR-phospholipid aggregates [40], which could affect the organization of liposomes and 
their interactions with Cu
2+
.  
Oximetry was applied to further examine the stoichiometry and the involvement of O2 in redox 
interactions between BR and Cu
2+
. It is known that Cu
1+
 rapidly reacts with molecular oxygen at 
physiological pH to produce superoxide radical anion, which is further reduced/dismutated to H2O2 
[41,42]. The addition of BR to Cu
2+
 solutions induced a drastic drop in the concentration of O2 (Fig. 
4a). The decrease of [O2] was only slightly pronounced in systems with [Cu
2+
]/[BR] > 1 concentration 
ratio compared to the system with [Cu
2+
]/[BR] = 1 (142 ± 4 μM vs. 129 ± 11 μM; p > 0.05). In addition, 
M
AN
US
CR
IP
T
 
AC
CE
PT
ED
ACCEPTED MANUSCRIPT
 
 
the amount of consumed O2 in the system with [Cu
2+
]/[BR] = 0.5 was approximately one half of O2 
consumed in [Cu
2+
]/[BR] = 1 system. This further substantiates that one BR 'generates' one Cu
1+
. The 
consumption of O2 in [Cu
2+
]/[BR] = 1 system was significantly suppressed by PA (80 ± 15 μM; p = 
0.040). Following 10 min incubation period, CAT was added to estimate the concentration of H2O2. 
The incubation of 0.2 mM Cu
2+
 with 0.2 mM BR led to the accumulation of a significant amount of 
H2O2 (69 ± 17 μM). In the presence of 0.2 mM PA in this system, the concentration of accumulated 
H2O2 was halved (33 ± 11 μM; p = 0.044) (Fig. 4b). It is important to note that although PA has the 
capacity to bind both Cu
2+
 and Cu
1+
, it shows much higher affinity for the latter [43]. The level of O2 in 
all examined systems was not completely reversed by the addition of CAT. Clearly, some amount of 
H2O2 is lost, most likely via Fenton-like reaction that generates highly reactive hydroxyl radical (Cu
1+
 + 
H2O2 → Cu
2+
 + OH
-
 + HO
•
) [44].  
Redox interactions of BR and copper result in the formation of Cu
1+
 and the production of H2O2 and 
HO
•
. Cu
1+
 and HO
•
 may initiate lipid peroxidation and damage cell membranes [45], whereas H2O2 
crosses the membrane to 'hit' intracellular targets [28]. Pertinent to this, the effects of BR-Cu
2+
 
system on human erythrocytes and the protective capacity of PA were examined, using extracellular 
MDA and hemoglobin as markers of lipid peroxidation and hemolysis (Fig. 5). It is important to note 
that Cu
2+ 
was applied at concentration that matches the range previously reported for the plasma of 
neonates with hyperbilirubinemia [14]. It can be observed that Cu
2+
 and BR induced lipid 
peroxidation and hemolysis, which is in line with previous reports [46,47]. Such effects have been 
related to redox interactions of Cu
2+
 with cellular membranes [45,47], and to the mechanical effects 
of BR on erythrocyte membrane [48]. Importantly, lipid peroxidation and hemolysis were significantly 
more pronounced in erythrocytes exposed simultaneously to Cu
2+
 and BR. PA alleviated the damage, 
but the markers of peroxidation and hemolysis were still higher compared to control values. It is 
plausible that PA prevents pro-oxidative activity of Cu
2+
 in the presence of BR via sequestration, 
whereas the direct effects of BR on the membranes remained. It is important to note here that the 
plasma concentrations of unconjugated BR in severe hyperbilirubinemia have been estimated at ~20 
nM [7]. So the direct effects of BR on cell membranes might be less important compared to the 
synergistic effects of Cu
2+
 and BR. 
In conclusion, BR reduces Cu
2+
 (to Cu
1+
) in 1:1 stoichiometry. This is accompanied by Cu
1+
-induced 
reduction of O2 that results in H2O2 accumulation and HO
•
 production. The sequestration of copper 
by PA diminished redox interplay and alleviated the damaging effects on membranes. The binding of 
Cu
2+
 to liposomes prevented BR-induced reduction, but it appears that such mechanism does not 
take place at erythrocytes membrane. The elucidated mechanisms warrant further research on the 
potential benefits of copper-chelation therapy in the treatment of neonatal hyperbilirubinemia. It is 
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noteworthy that PA appears not to exhibit significant short-term side-effects in infants [49]. In 
addition, other copper-sequestrating agents are available (triethylenetetramine; appears to show 
less side-effects in adults compared to PA), or are being tested for the treatment of Wilson's disease 
(e.g. tetrathiomolybdate) [50].  
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FIGURE LEGENDS 
 
Fig. 1. UV-Vis spectra of bilirubin (BR) in the absence or presence of Cu
2+
 or Fe
3+
 in 50 mM phosphate 
buffer, pH 7.4. (a) Changes in spectra of 0.1 mM BR in the presence of 0.2 mM Cu
2+
 during 30 min 
(spectra were acquired every 5 min). Changes are marked with arrows. (b) Spectra of 0.1 mM BR 
before and after 30 min of incubation in the absence or the presence of 0.2 mM Fe
3+
.  
Color: in online only. 
 
Fig. 2. Cyclic and differential pulse voltammograms of copper and bilirubin (BR)-Cu
2+
 in water, pH ~5, 
at boron-doped diamond electrode. (a) Cyclic voltammograms (scan rate 0.1 V/s) of 0.1 mM CuCl and 
0.4 mM CuCl2 with labeled peak current oxidation/anodic (Epa) and reduction/cathodic (Epc) 
potentials. (b) Changes (marked with arrows in the enlargement) in cyclic voltammograms (scan rate 
0.1 V/s) of copper in the presence of 0.2 mM BR. Arrowhead marks a time-depended decrease of the 
current at Epa = -217 mV. (c) Differential pulse voltammograms (increment, 0.004 V; pulse width, 0.05 
s; sample width, 0.01 s; quiet time, 2 s) of Cu
2+
 at different concentrations in the absence or the 
presence of 0.2 mM BR.  
Color: in online only. 
 
Fig. 3. 110 K EPR spectra of Cu
2+
 in the absence or the presence of 0.2 mM bilirubin (BR) after 30 s 
incubation period. (a) 0.2 mM Cu
2+
, and 0.2 mM Cu
2+
 + BR, in 50 mM phosphate buffer, pH 7.4. 
Arrowheads – positions of 4 lines coming from the hyperfine splitting along g║. ΔB┴ – line widths of 
g┴ signals before and after the incubation with BR. (b) 0.2 mM Cu
2+
 + 0.2 mM penicillamine (PA) in 
the absence or the presence of BR in 50 mM phosphate buffer, pH 7.4. Arrow – a broad line of 
penicillamine-bound Cu
2+
. (c) Cu
2+
 + liposomes, and Cu
2+
 + liposomes + BR in water. Dotted line: 0.2 
mM Cu
2+
 in the phosphate buffer (for reference).  
 
Fig. 4. The consumption of molecular oxygen in different bilirubin (BR)-Cu
2+
 systems in 50 mM 
phosphate buffer, pH 7.4. (a) Changes in O2 concentration and O2 consumption rate induced by the 
addition of BR to Cu
2+
 solutions. (b) The effects of 0.2 mM PA on O2 consumption (rate) in the system 
with 0.2 mM Cu
2+
 and 0.2 mM BR. H2O2 accumulation was quantified 10 min after the addition of BR, 
by CAT-induced O2 release (2H2O2 → 2H2O + O2). Arrowheads – artifact that emerged with BR 
supplementation. Color: in online only. 
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Fig. 5. Effects of 10 μM bilirubin (BR) and 10 μM Cu
2+
 on erythrocytes, in the absence or the presence 
of 20 μM penicillamine (PA) following 5 min incubation at 37
o
C in the phosphate buffer saline, pH 
7.4. (a) The extracellular concentration of the product of lipid peroxidation – MDA. (b) The amount of 
extracellular hemoglobin, which is a marker of hemolysis. Bars not sharing a common letter are 
significantly different (p < 0.05; one-way ANOVA with post hoc Duncan’s range test). 
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– Bilirubin reduces Cu
2+
 in 1:1 stoichiometry 
– Cu
1+
 undergoes spontaneous oxidation resulting in reactive oxygen species production 
– Copper and bilirubin induce oxidative damage in cell membranes 
– Redox interactions of Cu
2+
 and bilirubin are hampered by penicillamine and phosphates 
